All News

Part 2 - Modelling a Better Dose: Using MIDD to meet Regulatory Expectations & Make Smarter Decisions in Drug Development     In the previous blog post, we introduced the FDA guidance “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases”, concepts related to Project Optimus and how these impact different parts of the industry.   This time, we want to dig...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a sizeable contract extension award with an existing large pharma client.   The project builds upon the contract award announced on 13 June 2024, where the Company’s proprietary Virtual Tumour platform has been used to model the client’s targeted oncology...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce its attendance at the upcoming ASCPT 2025 Annual Meeting, taking place May 28-30, 2025, in Washington, DC.   The American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting is a leading global event bringing together researchers, industry leaders, and...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of population Pharmacokinetic (PK) modelling techniques using Phase 1 data to inform the Phase 2 study of a small molecule designed to treat rheumatoid arthritis....

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a contract award with a new UK client.   The project will involve the application of modelling and simulation techniques to support the development of a first-in-class bifunctional antibody therapy designed to target multiple solid tumour indiciations. More specifically, Pharmacokinetic...

Read More

Part 1 of 2 – Embracing a New Era of Dose Optimisation   For the last few years the FDA has been engaging with drug developers to reform how dose optimisation is approached for new cancer drugs. In August 2024 they finalised the eagerly-awaited guidance for industry “Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases” [1]. As part...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the joint online publication in collaboration with Ankyra Therapeutics entitled ‘A pharmacokinetic and pharmacodynamic model of an interleukin-12 (IL-12) anchored-drug conjugate for the treatment of solid tumors’ in the Journal of Molecular Cancer Therapeutics, American Association for Cancer...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce a new contract with its long-standing client, Numab Therapeutics AG.   The project will involve the application of modelling and simulation techniques to inform pre-clinical development of a multi-specific antibody designed to activate anti-tumor immune responses for the treatment of...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is delighted to announce a contract award with a new UK-based biotech company developing antibody drug conjugates (ADCs) based therapies targeting hard-to-treat cancers.   This new project will see the Company develop a Pharmacokinetic (PK) Pharmacodynamic (PD) model to inform optimal dosing for the...

Read More

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its Interim Results via Investor Meet Company and has updated its website with the presentation.   The presentation and Q&A from the meeting are now available at the Company’s website: https://www.physiomics.co.uk/portfolio-item/investor-presentation-company-update-2/     Enquiries:   Physiomics plc Dr Jim Millen, Non-Executive Chairman Dr Peter...

Read More